Clinical Trials Directory
Participants will complete various surveys about their health and experience with their new bowel program.
We are doing this study to find the most safe and effective long-term dose of an experimental drug called zanubrutinib (the study drug) when it is given alone or in combination with other cancer drugs. We want to know how well this study drug works in people with B-cell cancers who are currently participating or previously participated in a BeiGene-sponsored study.
If you join the study, you will be placed into one of two treatment groups. One group will get a sling called a retropubic mid-urethral sling (RP-MUS). The other group will get a treatment called urethral bulking with a gel called polyacrylamide gel (PAHG). After the procedure, you will have check-up visits at 1 month, 6 months, 12 months, and 24 months. You can also choose to take part in interviews about your experience.
We are doing this study to monitor the health of the cornea in participants with neovascular age-related macular degeneration (nAMD), also know as wet AMD, who receive an eye implant that continuously delivers the drug ranibizumab into the back of the eye.
The study has 4 parts: screening, taking the study drug, stopping the drug, and follow-up. You’ll get tests like blood work, heart checks, and scans. You’ll be randomly given one of two medicines: BGB-16673 or Pirtobrutinib, both taken once a day. After stopping the medicine, you’ll return for a check-up in about a month. If your cancer hasn’t gotten worse, you’ll visit every 6 months. If it has, the study team will check on you by phone or email. The whole study may last about 3 years with around 13 visits.
We are doing this study to find the most effective, safe dose of an experimental drug called ficerafusp alfa (BCA101 - the study drug) when it is given in combination with pembrolizumab for people who have metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
We are doing this study to find out if an experimental drug called pegozafermin (the study drug) is a safe and effective option for people who have compensated liver cirrhosis due to MASH.